Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

777 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
Takano T, Ohe Y, Tsuta K, Fukui T, Sakamoto H, Yoshida T, Tateishi U, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Matsuno Y, Furuta K, Tamura T. Takano T, et al. Among authors: furuta k. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5385-90. doi: 10.1158/1078-0432.CCR-07-0627. Clin Cancer Res. 2007. PMID: 17875767
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, Furuta K, Shimada Y, Ogiwara H, Watanabe S, Nokihara H, Yasuda K, Hiramoto M, Nammo T, Ishigame T, Schetter AJ, Okayama H, Harris CC, Kim YH, Mishima M, Yokota J, Yoshida T, Kohno T. Nakaoku T, et al. Among authors: furuta k. Clin Cancer Res. 2014 Jun 15;20(12):3087-93. doi: 10.1158/1078-0432.CCR-14-0107. Epub 2014 Apr 11. Clin Cancer Res. 2014. PMID: 24727320 Free PMC article.
Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
Yagishita S, Horinouchi H, Katsui Taniyama T, Nakamichi S, Kitazono S, Mizugaki H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Sumi M, Shiraishi K, Kohno T, Furuta K, Tsuta K, Tamura T. Yagishita S, et al. Among authors: furuta k. Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):140-8. doi: 10.1016/j.ijrobp.2014.08.344. Epub 2014 Oct 13. Int J Radiat Oncol Biol Phys. 2015. PMID: 25442336
Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.
Fukui T, Ohe Y, Tsuta K, Furuta K, Sakamoto H, Takano T, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Asamura H, Tsuchida T, Kaneko M, Kusumoto M, Yamamoto S, Yoshida T, Tamura T. Fukui T, et al. Among authors: furuta k. Clin Cancer Res. 2008 Aug 1;14(15):4751-7. doi: 10.1158/1078-0432.CCR-07-5207. Clin Cancer Res. 2008. PMID: 18676744
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.
Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Furuta K, Tamura T. Takano T, et al. Among authors: furuta k. J Clin Oncol. 2008 Dec 1;26(34):5589-95. doi: 10.1200/JCO.2008.16.7254. Epub 2008 Sep 15. J Clin Oncol. 2008. PMID: 18794545
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.
Kozu Y, Tsuta K, Kohno T, Sekine I, Yoshida A, Watanabe S, Tamura T, Yokota J, Suzuki K, Asamura H, Furuta K, Tsuda H. Kozu Y, et al. Among authors: furuta k. Lung Cancer. 2011 Jul;73(1):45-50. doi: 10.1016/j.lungcan.2010.11.003. Epub 2010 Dec 3. Lung Cancer. 2011. PMID: 21129809
777 results